Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor

Abstract Aims This study aims to determine whether adjuvant treatment with imatinib improves recurrence-free survival (RFS) in Chinese patients undergoing complete resection of localized primary gastrointestinal stromal tumor (GIST) compared with those not receiving adjuvant therapy. We also sought...

Full description

Saved in:
Bibliographic Details
Published in:European journal of surgical oncology 2011-04, Vol.37 (4), p.319-324
Main Authors: Li, J, Gong, J.F, Wu, A.W, Shen, L
Format: Article
Language:English
Subjects:
Adjuvant therapy
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Asian Continental Ancestry Group
Benzamides
c-KIT
Chemotherapy, Adjuvant
China
Disease-Free Survival
Drug Administration Schedule
Female
Gastrectomy
Gastrointestinal stromal tumor
Gastrointestinal Stromal Tumors - drug therapy
Gastrointestinal Stromal Tumors - mortality
Gastrointestinal Stromal Tumors - surgery
Hematology, Oncology and Palliative Medicine
Humans
Imatinib
Imatinib Mesylate
Kaplan-Meier Estimate
Male
Middle Aged
Mutation
Piperazines - administration & dosage
Piperazines - therapeutic use
Proportional Hazards Models
Prospective Studies
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - therapeutic use
Proto-Oncogene Proteins c-kit - genetics
Pyrimidines - administration & dosage
Pyrimidines - therapeutic use
Recurrence-free survival
Risk Assessment
Risk Factors
Surgery
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aims This study aims to determine whether adjuvant treatment with imatinib improves recurrence-free survival (RFS) in Chinese patients undergoing complete resection of localized primary gastrointestinal stromal tumor (GIST) compared with those not receiving adjuvant therapy. We also sought a correlation between c-KIT mutations and RFS. Methods Patients who had undergone complete tumor resection with intermediate or high risk of recurrence were enrolled in a single-center, non-randomized, prospective study. Patients either received adjuvant imatinib therapy (400 mg once-daily) for 3 years or did not. Mutation analyses of c-KIT were performed on available archival tumor samples. Results 105 patients were enrolled: 56 in the treatment group and 49 in the control group. Median follow-up was 45(43.1–46.9) months. RFS at 1, 2 and 3 years were higher in the treatment group than in the control group (100% vs. 90% at 1 year; 96% vs. 57% at 2 years; 89% versus 48% at 3 years, P  
ISSN:0748-7983
1532-2157
DOI:10.1016/j.ejso.2011.01.005